The global equine healthcare market size reached USD 1.6 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 2.6 Billion by 2033, exhibiting a growth rate (CAGR) of 5.31% during 2025-2033. The rapid increase in the equine population, rising awareness among owners regarding equine health and proper nutrition, and the utilization of advanced imaging techniques represent some of the key factors driving the market.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024
|
Forecast Years
|
2025-2033
|
Historical Years
|
2019-2024
|
Market Size in 2024 | USD 1.6 Billion |
Market Forecast in 2033 | USD 2.6 Billion |
Market Growth Rate (2025-2033) | 5.31% |
Equine healthcare is a branch of veterinary medicine that focuses on the diagnosis, treatment, and prevention of diseases in horses. It involves the utilization of various products, such as vaccines, dewormers, topical treatments, joint supplements, prebiotics, fly sprays, hoof conditioners, antiseptics, and performance additives. Equine healthcare includes preventive care, illness management, lameness treatment, reproductive care, oral hygiene, rehabilitation, and addressing behavioral issues. It assists in improving overall health, preventing future complications, allowing early disease detection, facilitating successful breeding, promoting a longer lifespan, and reducing the risk of serious diseases, such as lameness, dental problems, infections, obesity, herpes, and rabies.
The rapid increase in the equine population due to the widespread utilization of horses in racing, farming, and as companions is one of the primary factors propelling the market growth. Equine healthcare services and products, such as preventive care, reproductive services, rehabilitation centers, vaccines, and health supplements, are widely used to ensure optimum performance, prevent complications, protect from injuries, and reduce the risk of illnesses. In addition to this, rising awareness among the owners regarding the importance of equine health and proper nutrition is acting as another growth-inducing factor. Furthermore, the implementation of various government initiatives to support animal welfare, promote responsible ownership, and provide access to high-quality healthcare facilities is positively influencing the market growth. Additionally, the utilization of advanced imaging techniques, such as digital radiography, ultrasound, and endoscopy, to provide detailed cross-sectional images of the horse's body, thus allowing the diagnosis of musculoskeletal injuries, lameness, and internal diseases, is contributing to the market growth. Besides this, the recent development of wearable health monitoring devices for horses, which allows continuous monitoring of vital signs, activity levels, and behavior to facilitate early detection of any health issues, is providing an impetus to the market growth. Moreover, the growing number of equine sports, such as racing, jumping, dressage, and endurance riding, is propelling the market growth. Other factors, including rising expenditure capacities of consumers, emerging trends of pet humanization, extensive research and development (R&D) activities, and rapid expansion of the e-commerce industry, are anticipated to drive the market growth.
IMARC Group provides an analysis of the key trends in each segment of the global equine healthcare market, along with forecasts at the global, regional, and country levels from 2025-2033. Our report has categorized the market based on product, indication, and distribution channel.
Product Insights:
The report has provided a detailed breakup and analysis of the equine healthcare market based on the product. This includes drugs (anti-inflammatory drugs, parasiticide drugs, and others), vaccines (live attenuated vaccine, recombinant vaccine, and others), medicated feed additives, diagnostics, and others. According to the report, drugs represented the largest segment.
Indication Insights:
A detailed breakup and analysis of the equine healthcare market based on the indication has also been provided in the report. This includes musculoskeletal disorders, parasite control, equine herpes virus, equine encephalomyelitis, equine influenza, West Nile virus, tetanus, rabies, and others. According to the report, parasite control accounted for the largest market share.
Distribution Channel Insights:
A detailed breakup and analysis of the equine healthcare market based on the distribution channel has also been provided in the report. This includes veterinary hospitals and clinics and retail pharmacies and drug stores. According to the report, veterinary hospitals and clinics accounted for the largest market share.
Regional Insights:
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for equine healthcare. Some of the factors driving the North America equine healthcare market included the rising equine population, supportive government policies, and significant technological advancements.
The report has also provided a comprehensive analysis of the competitive landscape in the global equine healthcare market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Boehringer Ingelheim International GmbH, Ceva, Dechra Pharmaceuticals PLC, Elanco Animal Health Incorporated, Esaote SpA, Hallmarq Veterinary Imaging, IDEXX Laboratories Inc., Merck & Co. Inc., Vetoquinol S.A., Zoetis Inc, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Billion USD |
Products Covered |
|
Indications Covered | Musculoskeletal Disorders, Parasite Control, Equine Herpes Virus, Equine Encephalomyelitis, Equine Influenza, West Nile Virus, Tetanus, Rabies, Others |
Distribution Channels Covered | Veterinary Hospitals and Clinics, Retail Pharmacies and Drug Stores |
Regions Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | Boehringer Ingelheim International GmbH, Ceva, Dechra Pharmaceuticals PLC, Elanco Animal Health Incorporated, Esaote SpA, Hallmarq Veterinary Imaging, IDEXX Laboratories Inc., Merck & Co. Inc., Vetoquinol S.A., Zoetis Inc, etc. |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |